Who Shaped Oncology in the First Half of 2026: The Researchers Behind the Breakthroughs

Who Shaped Oncology in the First Half of 2026: The Researchers Behind the Breakthroughs

In the first half of 2026, the U.S. Food and Drug Administration approved 22 drugs across 15 distinct indications in oncology. Behind these pivotal trials that led to the approvals are the principal investigators whose names are often not discussed when talking about the practice-changing historical impact resulting from the trials.  In this article, we spotlight the Principal Investigators of oncology clinical trials that resulted in FDA approvals in the first half of 2026.

About this data

We searched the FDA website for oncology drug and biologic approvals made between January 1 and June 30, 2026, and extracted data on each approval’s trial name, approved drug name(s), approval date, approved indication(s), and responsible party. This search identified 22 approvals across distinct tumor types.

For each of the 22 approvals in this window, we identified the trial’s principal investigator and their primary academic institution: whoever was named the global or lead PI, or came up most consistently in that role across trial registries, sponsor communications, and the trial’s main publication.

Key PIs and where they come from

Home for “starring” Principal Investigators in 2026 was not surprisingly the United States.

ImagesName and InstitutionMilestone
Saad Z. UsmaniSaad Z. Usmani, Memorial Sloan Kettering Cancer CenterCEPHEUS - D-VRd in newly diagnosed, transplant ineligible multiple myeloma
Jennifer R. BrownJennifer R. Brown, Dana-Farber Cancer Institute / Harvard Medical SchoolAMPLIFY - acalabrutinib + venetoclax in previously untreated CLL/SLL
Scott KopetzScott Kopetz, The University of Texas MD Anderson Cancer CenterBREAKWATER - encorafenib + cetuximab in metastatic BRAF V600E-mutant colorectal cancer
John HeymachJohn Heymach, The University of Texas MD Anderson Cancer CenterBeamion LUNG-1 - zongertinib in HER2-aberrant NSCLC
AlisonAlison Schram, Memorial Sloan Kettering Cancer CentereNRGy - zenocutuzumab in NRG1 fusion-positive cholangiocarcinoma
Michael WangMichael Wang, The University of Texas MD Anderson Cancer CenterSonrotoclax trial in relapsed/refractory mantle cell lymphoma
Naveen PemmarajuNaveen Pemmaraju, The University of Texas MD Anderson Cancer CenterPivekimab sunirine trial in blastic plasmacytoid dendritic cell neoplasm
Toni K. ChoueiriToni K. Choueiri, Dana-Farber Cancer Institute / Harvard Medical SchoolMK-6482-022 - belzutifan + pembrolizumab in adjuvant clear cell renal cell carcinoma
Otto MetzgerOtto Metzger, Dana-Farber Cancer Institute / Harvard Medical SchoolAlliance Foundation Trials study - palbociclib + trastuzumab in HR+/HER2+ metastatic breast cancer
Luciano J. CostaLuciano J. Costa, University of Alabama at Birmingham (UAB) O'Neal Comprehensive Cancer CenterMajesTEC-3 - Tec-Dara in relapsed/refractory multiple myeloma
Alex F. HerreraAlex F. Herrera, City of Hope SWOG S1826 - nivolumab + AVD in newly diagnosed advanced-stage Hodgkin lymphoma
Alexander B. OlawaiyeAlexander B. Olawaiye, Magee-Women's Hospital, University of Pittsburgh Medical Center (UPMC) ROSELLA - relacorilant + nab-paclitaxel in platinum-resistant ovarian cancer
Erika P. HamiltonErika P. Hamilton, Sarah Cannon Research InstituteVERITAC-2 - vepdegestrant in ESR1-mutated, HER2-negative advanced breast cancer
Michael R. SavonaMichael R. Savona, Vanderbilt University Medical CenterDecitabine/cedazuridine + venetoclax in acute myeloid leukemia
Everett H. MeyerEverett H. Meyer, Stanford University School of MedicinePrecision-T - Orca-T as an alternative to standard-of-care allogeneic transplant
Which institutions had the biggest share?

BIGR - institutions

University of Texas MD Anderson Cancer Center

UT MD Anderson leads the list. One of the largest cancer hospitals in the world holds its position not only in quality care but also continuous, impactful cancer research. Its investigators led 4 trials in this six-month window.

BIGR MD Anderson

  • Scott Kopetz serves as a Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology at MD Anderson. At the ESMO GI Cancers Congress 2026, he presented molecular analyses from the phase 3 BREAKWATER study.
  • John Heymach is the Chair and Professor in the Department of Thoracic/Head and Neck Medical Oncology and holds the prestigious Ruth Legett Jones Distinguished Chair. He presented the Beamion LUNG-1 trial during the European Lung Cancer Congress 2026.
  • Michael Wang ran the study behind sonrotoclax in mantle cell lymphoma. He is a Professor in the Department of Lymphoma & Myeloma.
  • Naveen Pemmaraju led the pivekimab sunirine trial in blastic plasmacytoid dendritic cell neoplasm. He is a Professor in the Department of Leukemia.
Dana-Farber Cancer Institute

Dana-Farber brought oncology new regimens from hematology to breast cancer (as expected), with three separate investigators.

  • Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies. She is also a Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School. She led the phase 3 AMPLIFY trial, which she presented at the ASH 2024 Annual Meeting.
  • Toni Choueiri serves as Chief of the Lank Center for Genitourinary (GU) Oncology and co-leader of the Harvard Cancer Consortium Kidney Cancer Program. At the 2026 ASCO Genitourinary Cancers Symposium, he presented results from the phase 3 LITESPARK-022 trial.
  • Otto Metzger is a medical oncologist at Dana-Farber and a professor at Harvard Medical School. He led the phase 3 PATINA (AFT-38) trial, which he presented as a late-breaking abstract at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Dana-Farber’s lead investigators also hold academic appointments at Harvard Medical School.

Notably, Otto Metzger’s study was sponsored by Alliance Foundation Trials, making it one of the two academically sponsored studies on this list.

BIGR

Memorial Sloan Kettering Cancer Center

MSKCC is the home for two PIs whose research led to regulatory approvals:

  • Saad Usmani (CEPHEUS in newly diagnosed multiple myeloma). Dr. Usmani is a hematologist-oncologist specializing in the care of patients with multiple myeloma and other disorders affecting plasma cells.
  • Alison Schram (eNRGy in NRG1 fusion-positive cholangiocarcinoma), who serves as a Gynecologic Medical Oncologist at MSKCC.

BIGR chart

The global breakdown of the PI institutions

BIGR - global

Seven of the twenty-two trials were led by investigators from outside the United States. Six of them came from Europe, and one came from Asia.

ImageName and InsitutionMilestone
Nicoletta ColomboNicoletta Colombo, University of Milan / European Institute of Oncology KEYNOTE-B96/ENGOT-ov65 -pembrolizumab combination in platinum-resistant ovarian cancer
Thomas PowlesThomas Powles, Barts Cancer Institute at Queen Mary University of London (QMUL)ctDNA-guided adjuvant atezolizumab in muscle invasive bladder cancer
Nadia HarbeckNadia Harbeck, Breast Center at the LMU University Hospital, MunichDESTINY-Breast11 - neoadjuvant fam-trastuzumab deruxtecan in HER2-positive breast cancer 
Rebecca DentRebecca Dent, National Cancer Centre Singapore TROPION-Breast02 - datopotamab deruxtecan in first-line metastatic triple-negative breast cancer
Maria De SantisMaria De Santis, Charité Universitätsmedizin BerlinDurvalumab + BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer
Karim Fizazi Karim Fizazi, Institut Gustave Roussy / University of Paris Saclay, Villejuif, France CAPItello-281 - capivasertib + abiraterone + prednisone in PTEN-deficient prostate cancer
Javier CortesJavier Cortés, International Breast Cancer Center (IBCC) Sacituzumab govitecan trial in triple-negative breast cancer

BIGR Europe PI

In Asia, Rebecca Dent (National Cancer Centre Singapore) led TROPION-Breast02 in metastatic triple-negative breast cancer, the sole approval in this period with a lead PI based in Asia.

Conclusion

Looking at the pattern of the institution’s PIs come from, we can see that pharmaceutical sponsors often go to the same group of institutions to find investigators. Over 40 percent of all trials in a six-month window feature lead investigators from just three hospitals, so this shows where the industry turns when it needs the patient volume, infrastructure, and expertise to get a complex trial across the finish line.

The international sites don’t break that pattern either. Institut Gustave Roussy, Charité Universitätsmedizin Berlin, Barts Cancer Institute, and the University of Milan aren’t smaller centers getting their first pivotal trial. They’re the same tier of large and established institutions.

Going with familiar infrastructure is the safer choice for the sponsor, but if industry keeps returning to the same handful of institutions, newer and more diverse centers will never get the chance to build the infrastructure or experience that would let them be ready for the next one. Patients who need access to breakthrough treatment but don’t live near one of these regions and hospitals, whether for geographic, socioeconomic, or other reasons, may never have the option to enroll in the studies.

Most of the pivotal trials behind these approvals being completed at a small set of institutions is not a flaw in a single trial. But as a pattern repeated this many times over six months, it raises a real question: who gets to lead the next generation of cancer research, and who gets left out of it by default.

About BIGR

This study was conducted by the Boston Institute for Global Rankings (BIGR) – an academic initiative dedicated to transparent, data-driven evaluation of excellence in universities, medical centers, and healthcare professionals worldwide. With a focus on performance, impact, and innovation, BIGR aims to create meaningful global benchmarks for the future.

Think BIGR 

Read our previous articles analyzing the 2026 FDA approvals in oncology:

Who Shaped Oncology in the First Half of 2026: The Researchers Behind the Breakthroughs

Ani Minasaryan
Fact checked by Ani Minasaryan MD, KOL Intelligence Lead of BIGR, Editor at OncoDaily
Elen Baloyan
Medically reviewed by Elen Baloyan MD, Medical Oncologist, Vice President of News and Content strategy, OncoDaily, P53, Director of BIGR, Editor-in-Chief of OncoDaily Magazine